Next-generation heart bypass grafts to naturally restore cardiovascular function.broad
HeartRestore · Horizon Europe grant · 2022-12-01–2025-11-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATOROPEN-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATOROPEN-01. CORDIS record →
Objective
Coronary Artery Disease is caused by narrowing of heart arteries that supply blood, often due to atherosclerosis. Coronary artery bypass grafting (CABG) is the gold standard surgery to treat it, and it commonly involves harvesting patient’s veins from the legs as grafts. This collection affects patients causing chronic pain and costly complications. It also has a high failure rate with >20% implants occluded after 1 year.Xeltis has developed a unique restorative vascular graft (XABG) that eliminates the need for vein harvesting. The implant provides a homing structure for cells in which cardiac and vascular tissues can be naturally restored, with the related advantages and benefits for patients and the healthcare system. We have proven our technology in first niche applications, as well as completed pre-clinical studies successfully for XABG. Now, we plan to perform a full clinical validation to obtain a CE mark in Europe and start market deployment and commercial up-scaling.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| XELTIS BV | NL | coordinator | €2,481,701 | Yes |
| XELTIS AG | CH | thirdParty | €0 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.